Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A [1 ]
Lisak, L [1 ]
Dutt, D [1 ]
Dean, L [1 ]
Fantroy, L [1 ]
Syed, E [1 ]
Gezer, S [1 ]
Hsu, WT [1 ]
Goldberg, C [1 ]
Loew, J [1 ]
Venugopal, P [1 ]
机构：
[1] Rush Univ, MDS Ctr, Chicago, IL 60612 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4830
引用
收藏
页码：273B / 273B
页数：1
相关论文
共 50 条
  • [1] Cytopenias improve in response to amifostine pentoxifylline/ciprofloxacin/dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Qawi, H
    Naseer, OB
    Dar, S
    Lisak, L
    Andric, T
    Ali, SI
    Quadri, M
    Ahmed, B
    Venugopal, P
    Gezer, S
    Gregory, S
    Loew, J
    Robin, E
    Rifkin, S
    BLOOD, 1998, 92 (10) : 631A - 631A
  • [2] Combination of pentoxifylline (PTX), ciprofloxacin (Cipro), dexamethasone (PCD) with amifostine improves ineffective hematopoiesis in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Andric, T
    Qawi, H
    Venugopal, P
    Gezer, S
    Gregory, SA
    Hines, C
    Mundle, S
    Ali, A
    Shetty, V
    Mativi, BY
    Dar, S
    Loew, J
    Robin, EL
    Kozloff, M
    Galvez, A
    Rifkin, SD
    Alston, D
    Hernandez, BM
    Shah, R
    BLOOD, 1997, 90 (10) : 367 - 367
  • [3] Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) ± topotecan in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Dar, S
    Borok, R
    Lisak, L
    Andrews, C
    Ekbal, M
    Mazzoran, L
    Zorat, F
    Rifkin, S
    Robin, E
    Gregory, S
    Venugopal, P
    BLOOD, 1999, 94 (10) : 305A - 305A
  • [4] Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, L
    Little, L
    Ekbal, M
    du Rant, M
    Ali, E
    Nascimben, F
    Tareen, M
    Venugopal, P
    BLOOD, 2000, 96 (11) : 146A - 146A
  • [5] Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS).
    Raza, A
    Dutt, D
    Lisak, L
    Dean, L
    Fantroy, L
    Gezer, S
    Syed, E
    Goldberg, C
    Loew, J
    Hsu, WT
    Venugopal, P
    BLOOD, 2001, 98 (11) : 273B - 274B
  • [6] Patients with Myelodysplastic Syndromes benefit from therapy with Amifostine, Pentoxifylline, and Ciprofloxacin with Dexamethasone.
    Turken, O
    Orhan, B
    Ozturk, A
    Etiz, D
    Yaylaci, M
    Uskent, N
    BLOOD, 2001, 98 (11) : 276B - 276B
  • [7] Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
    Raza, A
    Qawi, H
    Lisak, L
    Andric, T
    Dar, S
    Andrews, C
    Venugopal, P
    Gezer, S
    Gregory, S
    Loew, J
    Robin, E
    Rifkin, S
    Hsu, WT
    Huang, RW
    BLOOD, 2000, 95 (05) : 1580 - 1587
  • [8] Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS)
    Candoni, A.
    Raza, A.
    Galili, N.
    Simeone, E.
    Buttignol, S.
    Silvestri, F.
    Fanin, R.
    LEUKEMIA RESEARCH, 2007, 31 : S119 - S119
  • [9] Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide
    Raza, A
    Lisak, L
    Little, L
    Andrews, C
    Meyer, P
    Ekbal, M
    Venugopal, P
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 103 - 104
  • [10] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
12345